Objective: Hypertension is a chronic disorder requiring lifelong treatment. This study is done to find out the percentage variation of cost among different brands of angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers (ARBs) used in hypertension.
Introduction
Hypertension is a long term medical condition resulting in high morbidity and mortality. It is an important risk factor for various diseases like coronary heart disease, stroke, congestive heart failure and impaired renal function (Kokiwar et al., 2012) . WHO rates hypertension as one of the most important cause of premature death worldwide. Prevalence of hypertension in India is reported to vary from 4-15% in urban and 2-8% in rural population (Sandozi and Emani, 2010) . The situation is more alarming as hypertension attributes for nearly 10% of all deaths (Patel V et al., 2011) . Antihypertensive therapy reduces the risk of morbidity and mortality. According to eighth Joint National Committee (JNC 8) (James et al., 2014) , Angiotensin converting enzyme (ACE) inhibitors and Angiotensin receptor blockers (ARBs) are the initial drugs of choice along with calcium channel blockers and thiazide diuretics for hypertension. ACE inhibitors are also recommended in patients with diabetes, cardiovascular disease (American Diabetes Association, 2010) as they have nephroprotective (Fioretto and Solini, 2005) and cardio protective properties.
There are many brands of the same drug available in Indian market with large difference in prices. The cost of medicines is a hurdle in treating the condition effectively. Due to lack of information on comparative drug prices and quality it becomes difficult for physicians to prescribe most economical treatment ( . This Paunikar and Bhave, 2015) affects the compliance and adherence to the treatment by the patients. Information generated from cost analysis studies will be helpful for both the doctors in choosing the correct medicine for their patients and for policy makers in successfully utilizing the available resources (Adama et al., 2003) . So the present study was done to analyze the variation of cost among different brands of ACE inhibitors and ARBs available in the Indian market.
Materials and methods
The study was done in the department of pharmacology of a teaching hospital in south India. Indian Drug Today (January -March 2017) was used to analyze the prices of ACE inhibitors and ARBs. The cost of a particular drug in the same dose and dosage forms being manufactured by different companies was compared. The cost of drugs in Indian rupee (INR) for 10 tablets was calculated for each brand. The difference between the maximum and minimum costs of the same drug manufactured by different pharmaceutical companies was calculated. The percentage cost variation and cost ratio were then calculated for each drug. The percentage variation in the cost of the drugs was calculated using the following formula (Jadhav et al., 2013) .
Cost ratio is calculated by the ratio of most expensive brand to least expensive brand of the same drug (Singh, 2016) . It helps to know how many times the most expensive formulation is costlier than the least expensive formulation of the same drug.
Exclusion criteria: The drugs manufactured by only one company; drugs with no cost information were excluded. Fixed dose combinations of more than two agents were also excluded.
Statistical analysis
The data collected was entered in Microsoft Excel 2007. Cost ratio and percentage cost variation were calculated. The data is represented in the form of tables and charts.
Results
The prices of total of 21 drugs (11 single and 10 combination preparations) belonging to ACE inhibitors and ARBs were analyzed. Percentage cost variation increases with increase in the no. of manufacturing companies. Table 1 shows the price variation among ACE inhibitors. Maximum cost variation was seen with Enalapril 5mg (4748%) while Perindopril 4mg showed minimum cost variation of 44.2% (Figure 1 ). The cost ratio ranged from 1.44 for perindopril 4mg to 48.48 for Enalapril 5mg. Table 2 shows price variation in ARBs. Maximum cost variation was seen with Valsartan 80 mg (494.2 %) while Candesartan 4mg showed minimum cost variation of 3% (figure 2). The cost ratio ranged from 1.03 for Candesartan 4mg to 5.94 for Valsartan 80 mg. Table 3 shows price variation in combination therapy. A total of 10 combinations were analyzed. In this Irbesartan + Hydrochlorothiazide (150 mg +12.5 mg) combination showed the maximum variation of 289.85 %, while Losartan + Ramipril (50 mg +2.5 mg) showed minimum variation of 4.12% (figure 3). Cost ratios of ACE inhibitors and ARBs as single therapy and combination therapy were given in figure 4, 5, 6 respectively.
Discussion
Hypertension is a chronic illness requiring long term www.ajpp.in treatment. The compliance of patient is significantly dependent on the cost of the prescribed medicines and higher cost means the compliance will be less (Rao, 2005) . Selection of cost effective brand will improve the compliance and the consequence of the treatment.
There is a high fluctuation in the minimum and maximum price of ACE inhibitors and ARBs. The cost variation was above 100%. Among ACE inhibitors, Enalapril (5 mg) shows maximum price variation of 4748% and among ARBs, Valsartan (80 mg) has the price variation of 494.2 %. Other similar studies in oral antidiabetic drugs (Rajesh and Hima Bindu, 2017) , antibiotics (Zubin, 2015) , antihistamines (Singh, 2016) found similar results. These www.ajpp.in Unlike developed countries, more than 80% health financing is borne by patients in India (Creese et al., 2004 , Mahal et al., 2010 . Studies have shown that providing a manual of comparative drug prices annotated with prescribing advice to physicians reduced their patients' drug expense especially in a disease like hypertension which needs long term treatment (Reichert et al., 2000) .
The National pharmaceutical pricing authority (NPPA), of Government of India controls drug prices in Indian market. It fixes the ceiling price of a drug based on essentiality of a drug and the pharmaceutical companies fix the price for their products equal to or below the ceiling price for that formulation; however, they cannot sell any medicine given in the drugs prices control order (DPCO) list at a cost higher than that fixed under this order (Drugs Prices Control Order. 2017 Often, the physicians and the patients prefer the expensive brand name drugs because they believe that the generic equivalent is inferior. The costly brand of same generic drug is scientifically proved to be in no way superior to its economically cheaper counterpart (Das et al., 2007) . Comparative evaluation on quality of branded drug and its generic counterpart must be made mandatory for generic manufacturer. It is essential to take action by the government in regulating the prices which can be affordable by a common man.
Conclusion
There is a wide variation in the prices of different brands of ACE inhibitors and ARBs. They have an important role in management of hypertension especially associated with comorbidities like diabetes, heart failure. The health care providers must be aware of the availability of low cost drugs and can select the cost effective ones based on the economic status of the patient. This reduces the economic burden on the patient and health care system.
